Studies on the basis for the properties of fibrin produced from fibrinogen-containing gamma ' chains

Department of Biomedical Sciences, College of Health Sciences, Marquette University, Schroeder Health Complex, 426, PO Box 1881, Milwaukee, WI 53233-1881, USA.
Blood (Impact Factor: 9.78). 11/2005; 106(8):2730-6. DOI: 10.1182/blood-2005-01-0240
Source: PubMed

ABSTRACT Human fibrinogen 1 is homodimeric with respect to its gamma chains (gammaA-gammaA'), whereas fibrinogen 2 molecules each contain one gammaA (gammaA1-411V) and one gamma' chain, which differ by containing a unique C-terminal sequence from gamma'408 to 427L that binds thrombin and factor XIII. We investigated the structural and functional features of these fibrins and made several observations. First, thrombin-treated fibrinogen 2 produced finer, more branched clot networks than did fibrin 1. These known differences in network structure were attributable to delayed release of fibrinopeptide (FP) A from fibrinogen 2 by thrombin, which in turn was likely caused by allosteric changes at the thrombin catalytic site induced by thrombin exosite 2 binding to the gamma' chains. Second, cross-linking of fibrin gamma chains was virtually the same for both types of fibrin. Third, the acceleratory effect of fibrin on thrombin-mediated XIII activation was more prominent with fibrin 1 than with fibrin 2, and this was also attributable to allosteric changes at the catalytic site induced by thrombin binding to gamma' chains. Fourth, fibrinolysis of fibrin 2 was delayed compared with fibrin 1. Altogether, differences between the structure and function of fibrins 1 and 2 are attributable to the effects of thrombin binding to gamma' chains.


Available from: Kevin R Siebenlist, Jun 03, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Fibrinogen is an abundant plasma protein that, when converted to fibrin by thrombin, provides the main building blocks for the clot. Dys-, a-, and hypo-fibrinogenemias have been variably linked to a normal phenotype, bleeding or even thrombosis. Meanwhile, increased fibrinogen concentrations in the blood have been associated with risk for thrombosis. More recently, studies have focussed on abnormal fibrin structure as a cause for thrombosis. Fibrin clots that have high fiber density and increased resistance to fibrinolysis have been consistently associated with risk for thrombosis. Fibrin structure measurements can (i) provide an overall assessment of hemostatic capacity of a sample, (ii) include effects of thrombin generation and fibrinogen concentrations, (iii) include effects of fibrinogen mutations, polymorphisms, and modifications, and (iv) give an indication of clot mechanical strength and resistance to fibrinolysis. A fibrinogen splice variation of the γ-chain (γ') is discussed as a model for changes in fibrin structure in relation to thrombosis. Results from prospective studies on fibrin structure are awaited. Studies of fibrin formation under flow, interactions of fibrin with blood cells, the mechanical properties of the fibrin clot, and nanoscale/molecular characterization of fibrin formation are likely to expose new causal mechanisms for the role of fibrin in thrombotic disease. Future studies into the causality and mechanisms may lead to new opportunities using fibrin structure in the diagnosis or treatment of thrombosis.
    Journal of Thrombosis and Haemostasis 06/2013; 11(s1). DOI:10.1111/jth.12229 · 5.55 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In a newly formed wound, the natural fibrin network provides the first temporary matrix for tissue repair. Topical application of fibrin to a new wound may improve wound healing. A matrix of the common natural γ´ fibrin variant may further improve wound healing because it is expected to have a different architecture and this will influence angiogenesis, because it possesses increased thrombin and factor XIII binding and decreased platelet binding, when compared with the common γA fibrin matrix. Our objective was to determine the effect of fibrinogen and its γA and γ´ variants on angiogenesis and wound healing. We used in vitro angiogenesis models and an in vivo rat full thickness excisional wound healing model. When comparing γA and γ' fibrin in vitro, more tube-like structures were formed on day 7 in γA fibrin than in γ' fibrin (13.83±6.12 AU vs 6.1±1.46 AU). Wounds treated with fibrin demonstrated improved healing in vivo with more perfusion (47±3% vs 26±4%, p<0.01 in placebo) and higher CD34 density score (2.0±0.4 vs 2.8±0.1, p<0.01) on day 21 with fibrin matrices when compared with placebo-treated wounds. Increased perfusion was observed in γA fibrin-treated wounds on day 21 (53±10% vs 41±7% for γ´ fibrin). The other parameters showed slightly improved (not significant) wound healing with γA fibrin compared to γ' fibrin matrices. In conclusion, the use of fibrin and fibrin variant matrices offers an interesting methodology to stimulate the wound healing process.
    Tissue Engineering Part A 06/2014; 21(1-2). DOI:10.1089/ten.TEA.2014.0020 · 4.70 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Salus online 14:1 Abrill 2010 Fibrinógeno γA/ γ´amma A/gamma Prima) p. 60 Fibrinógeno γA/ γ´amma A/gamma Prima) características, propiedades y su posible rol en el desarrollo de trastornos cardiovasculares El fibrinógeno A/ γ´amma A/gamma Prima) es una isoforma que resulta del procesamiento alternativo del ARNm que codifica para la cadena γ del fibrinógeno. Esta variante constituye entre el 8-15% del fibrinógeno plasmático circulante y la misma presenta una serie de propiedades bioquímicas y fisiológicas particulares que la diferencian del fibrinógeno γA/γA, la isoforma predominante de la circulación. El fibrinógeno γA/ γ´irve de transportador del Factor XIII de la coagulación e incrementa las concentraciones del mismo en el coágulo. Por ello esta implicado en el grado de estabilización de la malla de fibrina y la resistencia a la fibrinólisis. Por otra parte γA/ γ´resenta un sitio de alta afinidad capaz de fijarse al exositio II de la trombina y de esta manera inhibir a este importante factor de la coagulación, efecto conocido como Antitrombina I. Ciertos estudios clínicos revelan una asociación entre altos niveles de γA/ γénfermedad arterial coronaria. Sin embargo, investigaciones más recientes señalan que niveles bajos de esta isoforma del fibrinógeno están relacionados con enfermedad trombótica venosa posiblemente por la reducción de la actividad antitrombina.
    Salus 04/2010;